Skip to main content
PMC home page
Protein & Cell logoLink to Protein & Cell
. 2012 Dec 22;4(1):71–81. doi: 10.1007/s13238-012-2067-9

Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma

Yun Yang 1, Tian Xia 2, Ning Li 3, Jin Zhang 1, Yuan Yang 1, Wenming Cong 4, Qiang Deng 2, Ke Lan 2,✉, Weiping Zhou 1,✉
PMCID: PMC4875440  PMID: 23292895

Abstract

The p53 signaling pathway works as a potent barrier to tumor progression. Two single nucleotide polymorphisms (SNPs) in the gene loci of p53 pathway, p53 codon 72 Arg72Pro and MDM2 SNP309 (T > G), have been shown to cause perturbation of p53 function, but the effect of the two SNPs on the risk of hepatocellular carcinoma (HCC) remains inconsistent. This study investigated the influence of combined p53 Arg72Pro and MDM2 SNP309 on the risk of developing HCC in patients with chronic hepatitis B virus infection, and evaluated the significance of the two combined SNPs on patient prognosis. In total, 350 HCC patients, 230 non-HCC patients, and 96 healthy controls were genotyped for the p53 Arg72Pro and MDM2 SNP309. The combined p53 Pro/Pro and MDM2 G/G genotype was significantly associated with HCC risk (P = 0.047). Multivariate analysis indicated that combined p53 Pro/Pro and MDM2 G/G genotype was an independent factor affecting recurrence and survival (P < 0.05). Patients with combined p53 Pro/Pro and MDM2 G/G genotypes had a poorer prognosis than other genotypes, P < 0.01 for both disease-free survival (DFS) and overall survival (OS). DFS and OS rates also differed significantly between Barcelona Clinic Liver Cancer (BCLC) stage A patients with combined p53 Pro/Pro and MDM2 G/G and other genotypes (P < 0.05). Thus, the combined p53 Pro/Pro and MDM2 G/G genotype is associated with increased risk of developing HCC and is an independent adverse prognostic indicator in early stage HCC.

Electronic Supplementary Material

Supplementary material is available for this article at 10.1007/s13238-012-2067-9 and is accessible for authorized users.

Keywords: hepatocellular carcinoma, p53, MDM2, single nucleotide polymorphisms, prognosis

Electronic supplementary material

13238_2012_2067_MOESM1_ESM.pdf (175.9KB, pdf)

Supplementary material, approximately 175 KB.

Footnotes

These authors contributed equally to the work.

Electronic Supplementary Material

Supplementary material is available for this article at 10.1007/s13238-012-2067-9 and is accessible for authorized users.

Contributor Information

Ke Lan, Email: lanke@sibs.ac.cn.

Weiping Zhou, Email: ehphwp@126.com.

References

  1. Anzola M. Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat. 2004;11:383–393. doi: 10.1111/j.1365-2893.2004.00521.x. [DOI] [PubMed] [Google Scholar]
  2. Baptiste N., Friedlander P., Chen X.B., Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 2002;21:9–21. doi: 10.1038/sj.onc.1205015. [DOI] [PubMed] [Google Scholar]
  3. Blonski W., Kotlyar D.S., Forde K.A. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol. 2010;16:3603–3615. doi: 10.3748/wjg.v16.i29.3603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Boersma B.J., Howe T.M., Goodman J.E., Yfantis H.G., Lee D.H., Chanock S.J., Ambs S. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst. 2006;98:911–919. doi: 10.1093/jnci/djj245. [DOI] [PubMed] [Google Scholar]
  5. Bond G.L., Hu W., Bond E.E., Robins H., Lutzker S.G., Arva N.C., Bargonetti J., Bartel F., Taubert H., Wuerl P., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004;119:591–602. doi: 10.1016/j.cell.2004.11.022. [DOI] [PubMed] [Google Scholar]
  6. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology. 2004;127:S56–61. doi: 10.1053/j.gastro.2004.09.016. [DOI] [PubMed] [Google Scholar]
  7. Bruix J., Sherman M., Llovet J.M., Beaugrand M., Lencioni R., Burroughs A.K., Christensen E., Pagliaro L., Colombo M., Rodes J., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepat. 2001;35:421–430. doi: 10.1016/S0168-8278(01)00130-1. [DOI] [PubMed] [Google Scholar]
  8. Buendia M.A. Genetics of hepatocellular carcinoma. Semin Cancer Biol. 2000;10:185–200. doi: 10.1006/scbi.2000.0319. [DOI] [PubMed] [Google Scholar]
  9. Cescon D.W., Bradbury P.A., Asomaning K., Hopkins J., Zhai R., Zhou W., Wang Z., Kulke M., Su L., Ma C., et al. p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res. 2009;15:3103–3109. doi: 10.1158/1078-0432.CCR-08-3120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Clifford R.J., Zhang J., Meerzaman D.M., Lyu M.-S., Hu Y., Cultraro C.M., Finney R.P., Kelley J.M., Efroni S., Greenblum S.I., et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology. 2010;52:2034–2043. doi: 10.1002/hep.23943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dharel N., Kato N., Muroyama R., Moriyama M., Shao R.X., Kawabe T., Omata M. MDM2 promoter SNP309 is associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res. 2006;12:4867–4871. doi: 10.1158/1078-0432.CCR-06-0111. [DOI] [PubMed] [Google Scholar]
  12. Dumont P., Leu J.I.J., Della Pietra A.C., George D.L., Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33:357–365. doi: 10.1038/ng1093. [DOI] [PubMed] [Google Scholar]
  13. Edamoto Y., Hara A., Biernat W., Terracciano L., Cathomas G., Riehle H.M., Matsuda M., Fujii H., Scoazec J.Y., Ohgaki H. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer Suppl. 2003;106:334–341. doi: 10.1002/ijc.11254. [DOI] [PubMed] [Google Scholar]
  14. Edmondson H.A., Steiner P.E. Primary Carcinoma of the Liver - a Study of 100 Cases among 48,900 Necropsies. Cancer. 1954;7:462–503. doi: 10.1002/1097-0142(195405)7:3&#x0003c;462::AID-CNCR2820070308&#x0003e;3.0.CO;2-E. [DOI] [PubMed] [Google Scholar]
  15. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–2576. doi: 10.1053/j.gastro.2007.04.061. [DOI] [PubMed] [Google Scholar]
  16. Grochola L.F., Zeron-Medina J., Meriaux S., Bond G.L. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2010;2:a001032. doi: 10.1101/cshperspect.a001032. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Han J.Y., Lee G.K., Jang D.H., Lee S.Y., Lee J.S. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer. 2008;113:799–807. doi: 10.1002/cncr.23668. [DOI] [PubMed] [Google Scholar]
  18. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  19. Hino O., Tabata S., Hotta Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci U S A. 1991;88:9248–9252. doi: 10.1073/pnas.88.20.9248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Hirata H., Hinoda Y., Kikuno N., Kawamoto K., Suehiro Y., Tanaka Y., Dahiya R. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res. 2007;13:4123–4129. doi: 10.1158/1078-0432.CCR-07-0609. [DOI] [PubMed] [Google Scholar]
  21. Horikawa Y., Nadaoka J., Saito M., Kumazawa T., Inoue T., Yuasa T., Tsuchiya N., Nishiyama H., Ogawa O., Habuchi T. Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder. Oncol Rep. 2008;20:49–55. [PubMed] [Google Scholar]
  22. Kao J.H., Chen P.J., Lai M.Y., Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 2000;118:554–559. doi: 10.1016/S0016-5085(00)70261-7. [DOI] [PubMed] [Google Scholar]
  23. Kubbutat M.H., Jones S.N., Vousden K.H. Regulation of p53 stability by Mdm2. Nature. 1997;387:299–303. doi: 10.1038/387299a0. [DOI] [PubMed] [Google Scholar]
  24. Lai E.C., Lau W.Y. The continuing challenge of hepatic cancer in Asia. Surgeon. 2005;3:210–215. doi: 10.1016/S1479-666X(05)80043-5. [DOI] [PubMed] [Google Scholar]
  25. Leu J.D., Lin I.F., Sun Y.F., Chen S.M., Liu C.C., Lee Y.J. Association between MDM2-SNP309 and hepatocellular carcinoma in Taiwanese population. World J Gastroenterol. 2009;15:5592–5597. doi: 10.3748/wjg.15.5592. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Lin C.L., Kao J.H. Hepatitis B viral factors and clinical outcomes of chronic hepatitis B. J Biomed Sci. 2008;15:137–145. doi: 10.1007/s11373-007-9225-8. [DOI] [PubMed] [Google Scholar]
  27. Nault J.C., Zucman-Rossi J. Genetics of hepatobiliary carcinogenesis. Semin Liver Dis. 2011;31:173–187. doi: 10.1055/s-0031-1276646. [DOI] [PubMed] [Google Scholar]
  28. Neuveut C., Wei Y., Buendia M.A. Mechanisms of HBV-related hepatocarcinogenesis. J Hepat. 2010;52:594–604. doi: 10.1016/j.jhep.2009.10.033. [DOI] [PubMed] [Google Scholar]
  29. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2:533–543. doi: 10.1016/S1470-2045(01)00486-7. [DOI] [PubMed] [Google Scholar]
  30. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutat. 2007;28:622–629. doi: 10.1002/humu.20495. [DOI] [PubMed] [Google Scholar]
  31. Pim D., Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 2004;108:196–199. doi: 10.1002/ijc.11548. [DOI] [PubMed] [Google Scholar]
  32. Puisieux A., Ji J., Guillot C., Legros Y., Soussi T., Isselbacher K., Ozturk M. p53-mediated cellular response to DNA damage in cells with replicative hepatitis B virus. Proc Natl Acad Sci U S A. 1995;92:1342–1346. doi: 10.1073/pnas.92.5.1342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143–154. doi: 10.1055/s-2005-871194. [DOI] [PubMed] [Google Scholar]
  34. Silini E., Bottelli R., Asti M., Bruno S., Candusso M.E., Brambilla S., Bono F., Iamoni G., Tinelli C., Mondelli M.U., et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology. 1996;111:199–205. doi: 10.1053/gast.1996.v111.pm8698200. [DOI] [PubMed] [Google Scholar]
  35. Talseth B.A., Meldrum C., Suchy J., Kurzawski G., Lubinski J., Scott R.J. MDM2 SNP309 T > G alone or in combination with the TP53 R72P polymorphism does not appear to influence disease expression and age of diagnosis of colorectal cancer in HNPCC patients. Int J Cancer. 2007;120:563–565. doi: 10.1002/ijc.22339. [DOI] [PubMed] [Google Scholar]
  36. Toffoli G., Biason P., Russo A., De Mattia E., Cecchin E., Hattinger C.M., Pasello M., Alberghini M., Ferrari C., Scotlandi K., et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res. 2009;15:3550–3556. doi: 10.1158/1078-0432.CCR-08-2249. [DOI] [PubMed] [Google Scholar]
  37. Xiao M., Zhang L., Zhu X., Huang J., Jiang H., Hu S., Liu Y. Genetic polymorphisms of MDM2 and TP53 genes are associated with risk of nasopharyngeal carcinoma in a Chinese population. BMC cancer. 2010;10:147. doi: 10.1186/1471-2407-10-147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Yang L.Y., Fang F., Ou D.P., Wu W., Zeng Z.J., Wu F. Solitary large hepatocellular carcinoma a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg. 2009;249:118–123. doi: 10.1097/SLA.0b013e3181904988. [DOI] [PubMed] [Google Scholar]
  39. Yoon Y.J., Chang H.Y., Ahn S.H., Kim J.K., Park Y.K., Kang D.R., Park J.Y., Myoung S.M., Kim do Y., Chon C.Y., et al. MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis. 2008;29:1192–1196. doi: 10.1093/carcin/bgn090. [DOI] [PubMed] [Google Scholar]
  40. Yuen M.F., Hou J.L., Chutaputti A., Asia Pacific Working Party on Prevention of Hepatocellular, C. Hepatocellular carcinoma in the Asia pacific region. J Gastroenterol Hepat. 2009;24:346–353. doi: 10.1111/j.1440-1746.2009.05784.x. [DOI] [PubMed] [Google Scholar]
  41. Zhang X., Miao X., Guo Y., Tan W., Zhou Y., Sun T., Wang Y., Lin D. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Human Mutat. 2006;27:110–117. doi: 10.1002/humu.20277. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

13238_2012_2067_MOESM1_ESM.pdf (175.9KB, pdf)

Supplementary material, approximately 175 KB.

Articles from Protein & Cell are provided here courtesy of Oxford University Press

RESOURCES